Park Place Capital Corp Purchases 5,616 Shares of Pfizer Inc. (NYSE:PFE)

Park Place Capital Corp boosted its position in Pfizer Inc. (NYSE:PFE) by 74.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,204 shares of the biopharmaceutical company’s stock after purchasing an additional 5,616 shares during the quarter. Park Place Capital Corp’s holdings in Pfizer were worth $335,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. Beam Wealth Advisors Inc. raised its position in shares of Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock worth $728,000 after buying an additional 401 shares in the last quarter. Providence Capital Advisors LLC boosted its position in shares of Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after acquiring an additional 409 shares during the last quarter. Donaldson Capital Management LLC boosted its position in shares of Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock valued at $947,000 after acquiring an additional 410 shares during the last quarter. Noesis Capital Mangement Corp increased its position in shares of Pfizer by 2.6% in the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 413 shares during the last quarter. Finally, First Command Advisory Services Inc. increased its position in shares of Pfizer by 2.5% in the fourth quarter. First Command Advisory Services Inc. now owns 17,479 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 418 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $24.30 on Friday. The company has a 50-day simple moving average of $23.42 and a two-hundred day simple moving average of $24.85. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm has a market cap of $138.18 billion, a price-to-earnings ratio of 17.61, a PEG ratio of 0.88 and a beta of 0.57. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the business posted $0.82 EPS. Pfizer’s quarterly revenue was down 7.8% compared to the same quarter last year. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.08%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PFE. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.